Dose-exposure-response of CARDALIS® (benazepril/spironolactone) on the classical and alternative arms of the renin-angiotensin-aldosterone system in healthy dogs
The combined CARDALIS® product leads to dose-dependent alterations of RAAS metabolites. These results could help inform clinical trials in dogs with heart disease.
Authors
- Emilie Guillot (ORCID: https://orcid.org/0000-0002-6892-4176)
- Maria M. Merodio (ORCID: https://orcid.org/0000-0003-4724-2720)
- Jessica L. Ward (ORCID: https://orcid.org/0000-0002-9153-7916)
- Jonathan P. Mochel (ORCID: https://orcid.org/0000-0002-0997-3111)
- Elizabeth Manson
- Thomas Blondel (ORCID: https://orcid.org/0000-0001-6316-967X)
- Karin Allenspach (ORCID: https://orcid.org/0000-0002-2168-5809)
- Oliver Domenig (ORCID: https://orcid.org/0000-0002-5995-8753)
Institutions
- University of Georgia (US)
- Iowa State University (US)
- Département Santé Animale (FR)
- Ludwig Boltzmann Institute Applied Diagnostics (AT)
Publication Details
- Journal
- Journal of Veterinary Internal Medicine
- Published
- 2024-11-27
- DOI
- https://doi.org/10.1111/jvim.17255
- Citations
- 2
- Primary Topic
- Cardiovascular Conditions and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.81